Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOVER: Leronlimab + TAS-102 + Bevacizumab in MSS mCRC
NCT06699836Phase 2Active, not recruiting
- Sponsor
- CytoDyn Inc.
- Start
- Jun 2025
- Primary completion
- Jan 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of leronlimab in metastatic colorectal cancer (mCRC) (3 arms), sponsored by CytoDyn Inc. Primary endpoint: Efficacy of leronlimab in combination with trifluridine and tipiracil + bevacizumab at 12 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
leronlimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06699836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699836.